Skip to main content
HomeBook
Mental Health

Cognitive Decline Isn't Inevitable: The Modifiable Risk Factors That Matter Most

· 7 min read

"That's just normal aging" is the explanation most patients get when they mention losing their train of thought mid-sentence or walking into a room and forgetting why, and for most of them it's at least partly wrong. The Lancet Commission on dementia prevention, intervention, and care concluded in its 2020 report, updated again in 2024, that roughly 45 percent of dementia cases worldwide trace back to a defined, modifiable set of risk factors, not to genetics or an unavoidable consequence of getting older. That number reframes cognitive decline from something that simply happens to a person into something substantially shaped by conditions that are, at least in part, within reach: blood pressure, blood sugar, sleep quality, hearing, and inflammation among them. None of this erases genuine risk carried by family history or the APOE4 gene variant. It does mean that for the large majority of patients asking what they can actually do about memory that feels less sharp than it used to, the honest answer is: considerably more than they've usually been told.

The Case for Modifiable Risk

The Lancet Commission, led by psychiatrist Gill Livingston and an international panel of dementia researchers, identified twelve modifiable risk factors in its original 2020 analysis: less early-life education, hearing loss, hypertension, smoking, obesity, depression, physical inactivity, diabetes, low social contact, excessive alcohol consumption, traumatic brain injury, and air pollution. The 2024 update added two more, untreated vision loss and high LDL cholesterol, pushing the total attributable share of dementia risk from roughly 40 to 45 percent. These factors don't act independently or add up neatly; they interact and compound across a lifetime, which is part of why the Commission frames prevention as something that pays off most when it starts in midlife rather than after symptoms appear.

Hearing loss is the single largest factor on that list, and it's the one patients are most likely to dismiss as unrelated to brain health entirely. The ACHIEVE trial, a large randomized controlled study published in The Lancet in 2023, found that fitting hearing aids slowed cognitive decline by roughly 48 percent over three years in older adults already at elevated risk, a striking result for an intervention with none of the side-effect burden of a pharmaceutical. The leading explanation isn't that hearing loss directly damages the brain; it's that straining to parse unclear sound draws cognitive resources away from encoding and memory, and the social withdrawal that often follows untreated hearing loss removes a second protective factor, social engagement, at the same time. In my clinical experience, a hearing assessment is one of the most consistently skipped steps in an otherwise thorough cognitive workup, simply because it doesn't look like a brain test.

Metabolic and Vascular Health Are Brain Health

Autopsy studies consistently find that pure Alzheimer's pathology, amyloid plaques and tau tangles with no vascular contribution, is actually less common than mixed dementia, where vascular damage and neurodegenerative changes occur together. That finding reorients prevention toward the same levers used for cardiovascular risk: blood pressure, circulation, and blood sugar regulation all show up as dementia risk factors because the brain depends on an enormous, continuous blood supply and tolerates vascular insult poorly.

Insulin resistance deserves particular attention here. Neuropathologist Suzanne de la Monte's research describes Alzheimer's disease, in a meaningful subset of cases, as exhibiting features of brain-specific insulin resistance severe enough that some researchers have proposed calling it "type 3 diabetes." Impaired insulin signalling in brain tissue reduces glucose uptake by neurons, promotes amyloid-beta accumulation, and accelerates tau phosphorylation, the two hallmark pathological processes in Alzheimer's. This is why insulin resistance that doesn't show up on a standard fasting glucose is worth identifying well before cognitive symptoms appear, not after. Elevated homocysteine tells a related story: the Oxford-based VITACOG trial, published in PLOS ONE in 2010, found that B-vitamin supplementation slowed brain atrophy on MRI specifically in participants who started with elevated homocysteine levels, a correctable nutritional factor that rarely gets checked in a routine physical.

What Happens to the Brain Overnight Matters As Much As What Happens During the Day

The brain has its own waste-clearance system, the glymphatic pathway, described by Maiken Nedergaard's team at the University of Rochester in a landmark 2013 Science paper. It clears metabolic byproducts, amyloid-beta among them, almost exclusively during deep, slow-wave sleep, when brain cells shrink slightly and allow cerebrospinal fluid to flow more freely through the tissue. A 2014 JAMA Neurology study by Ooms and colleagues found that a single night of sleep deprivation raised cerebrospinal fluid amyloid-beta levels by roughly 6 percent, a measurable effect from one bad night, not a chronic pattern. Chronic insomnia and the cortisol dysregulation that often drives it isn't just a quality-of-life problem in this light; it's a nightly interruption of the brain's own cleanup process, repeated for years in people who've normalized poor sleep as simply how they are.

Chronic low-grade inflammation compounds the same problem from a different angle. Elevated hs-CRP has been associated with faster cognitive decline across multiple longitudinal cohorts, and a meaningful share of that inflammatory signal originates in the gut rather than the brain itself. The gut-brain connection runs in both directions, and a microbiome that's driving systemic inflammation adds to the cumulative burden the brain is trying to manage alongside blood sugar swings, poor sleep, and whatever vascular risk is already present.

Building a Brain-Protective Protocol

I don't treat cognitive complaints as a single thing to test for; I treat them as a cluster of independently measurable risk factors, each worth quantifying on its own. A thorough workup includes fasting insulin and HOMA-IR rather than fasting glucose alone, hs-CRP, homocysteine, an omega-3 index, vitamin D, and B12 and folate status, with APOE4 genotyping offered selectively to patients who want that information as part of a longer-term risk picture rather than a diagnosis. Where exposure history or symptom pattern warrants it, I'll add heavy metal testing through a comprehensive functional panel, since mercury and lead both have documented neurotoxic effects at levels well below what triggers acute symptoms.

The MIND diet, developed and studied by Rush University researchers led by Martha Clare Morris and published in Alzheimer's & Dementia in 2015, combines elements of the Mediterranean and DASH diets with a specific emphasis on berries and leafy greens; high adherence was associated with a 53 percent reduction in Alzheimer's risk in that cohort, among the largest effect sizes seen for any single dietary pattern. Aerobic exercise earns its place for a more specific reason than general health: a 2011 PNAS study by Kirk Erickson and colleagues found that a year of moderate aerobic exercise increased hippocampal volume by about 2 percent in older adults, effectively reversing a year or more of age-related volume loss, through exercise-induced increases in brain-derived neurotrophic factor (BDNF). Addressing elevated homocysteine with targeted B-vitamin repletion, correcting an omega-3 deficit, and treating the vascular and metabolic risk factors above as a priority, rather than an afterthought, round out the core of the protocol. IV nutrient repletion has a role for patients with confirmed deficits who need faster correction than oral supplementation allows, and I use targeted peptide protocols selectively, for patients who've already addressed the fundamentals above and are looking for additional cognitive and mitochondrial support. None of this reverses dementia that's already established. It's aimed at the much larger group of patients who still have time to change which direction the next decade of risk factors adds up to.

Key Takeaways

  • The Lancet Commission on dementia attributes roughly 45 percent of dementia risk worldwide to modifiable factors, including hearing loss, blood pressure, blood sugar, sleep, and inflammation, not to genetics or aging alone.
  • Untreated hearing loss is the single largest modifiable risk factor identified; the 2023 ACHIEVE trial found hearing aids slowed cognitive decline by about 48 percent over three years in higher-risk older adults.
  • Insulin resistance impairs glucose uptake and accelerates amyloid and tau pathology in the brain, which is why some researchers describe a subset of Alzheimer's disease as brain-specific "type 3 diabetes."
  • The glymphatic system clears amyloid-beta from the brain almost exclusively during deep sleep; even one night of sleep deprivation measurably raises amyloid levels, making chronic poor sleep a nightly disruption of the brain's own cleanup process.
  • Elevated homocysteine and chronic low-grade inflammation, including inflammation originating in the gut, both independently accelerate cognitive decline and are correctable once identified through testing.
  • The MIND diet and regular aerobic exercise are among the best-evidenced interventions available, with effect sizes, a 53 percent reduced Alzheimer's risk and measurable hippocampal volume gains respectively, that rival many pharmaceutical approaches.
Dr. Rigobert Kefferputz

Dr. Rigobert Kefferputz, ND

Naturopathic doctor on Salt Spring Island with over 14 years of clinical experience in integrative medicine. McGill University and Boucher Institute of Naturopathic Medicine graduate. Member of the Canadian Association of Naturopathic Doctors.

References & Further Reading

This article is for education and is not a substitute for individual medical advice. For background reading, these independent health authorities offer evidence-based information:

  • Anxiety — U.S. National Library of Medicine (MedlinePlus)
  • Depression — U.S. National Library of Medicine (MedlinePlus)
  • Stress and Your Health — NIH National Center for Complementary and Integrative Health
  • Ashwagandha — NIH National Center for Complementary and Integrative Health